{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:46:47Z","timestamp":1785743207966,"version":"3.56.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>According to two phase I\/II trials, ASCERTAIN-V and SAVE, the all-oral regimen of decitabine\u2013cedazuridine and venetoclax, with revumenib added in the latter study, could be an effective option for patients with acute myeloid leukemia who would otherwise receive intravenous or subcutaneous chemotherapy.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2026-0073","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:57:06Z","timestamp":1782547026000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral Regimens for AML Make Strides"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2026,6,27]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NW2026-0073\/786317\/Oral-Regimens-for-AML-Make-StridesOral-Regimens","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787101\/Oral-Regimens-for-AML-Make-StridesOral-Regimens","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787101\/Oral-Regimens-for-AML-Make-StridesOral-Regimens","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:14:56Z","timestamp":1785741296000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787101\/Oral-Regimens-for-AML-Make-StridesOral-Regimens"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,27]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2026-0073","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}